Lutris, Pharma

Lutris Pharma to Present Data from Its Phase 2 Trial of LUT014 Gel for the Treatment of Patients With EGFRI-Induced Acneiform Rash at the ESMO Gastrointestinal Cancers Congress 2025

Published on 08/07/2025 at 18:07 | prnewswire.co.uk

Lutris Pharma Israel Spain United Kingdom

View original content:https://www.prnewswire.co.uk/news-releases/lutris-pharma-to-present-data-from-its-phase-2-trial-of-lut014-gel-for-the-treatment-of-patients-with-egfri-induced-acneiform-rash-at-the-esmo-gastrointestinal-cancers-congress-2025-302482579.html

en | boerse | 67946024 |